...
首页> 外文期刊>European journal of pharmaceutical sciences >Co amorphous valsartan nifedipine system: Preparation, characterization, in vitro and in vivo evaluation
【24h】

Co amorphous valsartan nifedipine system: Preparation, characterization, in vitro and in vivo evaluation

机译:CO无定形缬沙坦Nifemipine系统:制备,表征,体外和体内评价

获取原文
获取原文并翻译 | 示例
           

摘要

Co amorphous systems are supersaturated drug delivery systems which offer a basic platform for delivery of multicomponent adducts (combination of more than one active pharmaceutical ingredient (API)) and/or as a fixed dose combination therapy, in addition to their potential to improve the apparent solubility, dissolution rate and ultimately bioavailability of poorly water soluble APIs. In the present work, a new drug-drug co amorphous system namely valsartan-nifedipine was prepared by quench cooling technique. Prepared co amorphous system was characterized for its solid state behavior with the help of Fourier Transform Infrared spectroscopy (FTIR), Differential Scanning Calorimetry (DSC) and Powder X Ray Diffractometry (PXRD). The optimized co amorphous system was stable for 1 month when exposed to accelerated stability condition (40 +/- 2 degrees C and 75 +/- 5% RH). The improved stability of amorphous nifedipine in co amorphous system was attributed to improved miscibility and intra and intermolecular non-covalent interactions mainly due to presence of hydrogen bonding between valsartan and nifedipine which was studied by FTIR analysis. Co amorphous systems were evaluated by mainly in vitro dissolution and in vivo benefit. In vitro dissolution study showed nearly 5.66 folds and 1.61 folds improvement which was translated to 3.63 and 2.19 times enhancement in vivo C-max for nifedipine and valsartan respectively.
机译:CO非晶系统是过饱和药物递送系统,其提供用于递送多组分加合物的基本平台(多于一种活性药物成分(API)的组合)和/或作为固定剂量组合疗法,除了它们的潜力改善明显溶解度,溶出速率和最终水溶性差距的生物利用度。在本作工作中,通过淬火冷却技术制备了一种新的药物 - 药物Co非晶系统即缬沙坦 - 硝基哌啶。制备的CO非晶系统的特征在于傅里叶变换红外光谱(FTIR),差示扫描量热法(DSC)和粉末X射线衍射法(PXRD)的帮助。在暴露于加速稳定条件(40 +/- 2℃和75 +/- 5%RH)时,优化的Co非晶系统稳定为1个月。在Co非晶体系中的无定形硝苯地平的改善稳定性归因于改善的混溶性和分子间非共价相互作用主要是由于FTIR分析研究的缬沙坦和硝苯地平之间的氢键存在。通过主要体外溶解和体内益处来评估CO非晶系统。体外溶解研究显示出近5.66倍和1.61倍的改善,分别转化为3.63和2.19倍的硝苯地平和缬沙坦的体内C-Max中的增强。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号